Whetstine Johnathan R, Flatley Robin M, Matherly Larry H
Department of Pharmacology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, U.S.A.
Biochem J. 2002 Nov 1;367(Pt 3):629-40. doi: 10.1042/BJ20020512.
Our previous study identified two alternate non-coding upstream exons (A and B) in the human reduced folate carrier (hRFC) gene, each controlled by a separate promoter. Each minimal promoter was regulated by unique cis -elements and transcription factors, including stimulating protein (Sp) 1 and Sp3 and the basic leucine zipper family of proteins, suggesting opportunities for cell- and tissue-specific regulation. Studies were performed to explore the expression patterns of hRFC in human tissues and cell lines. Levels of hRFC transcripts were measured on a multi-tissue mRNA array from 76 human tissues and tumour cell lines and on a multi-tissue Northern blot of representative tissues, each probed with full-length hRFC cDNA. hRFC transcripts were ubiquitously expressed, with the highest level in placenta and the lowest level in skeletal muscle. By rapid amplification of cDNA 5'-ends assay from nine tissues and two cell lines, hRFC transcripts containing both A and B 5'-untranslated regions (UTRs) were identified. However, five additional 5'-UTRs (designated A1, A2, C, D and E) were detected, mapping over 35 kb upstream from the hRFC translation start site. The 5'-UTRs were characterized by multiple transcription start sites and/or alternative splice forms. At least 18 unique hRFC transcripts were detected. A novel promoter was localized to a 453 bp fragment, including 442 upstream of exon C and 11 bp of exon C. A 346 bp repressor flanked the 3'-end of this promoter. Our results suggest an intricate regulation of hRFC gene expression involving multiple promoters and non-coding exons. Moreover, they provide a transcriptional framework for understanding the role of hRFC in the pathophysiology of folate deficiency and antifolate drug selectivity.
我们之前的研究在人类还原型叶酸载体(hRFC)基因中鉴定出两个交替的非编码上游外显子(A和B),每个外显子由一个单独的启动子控制。每个最小启动子由独特的顺式元件和转录因子调控,包括刺激蛋白(Sp)1和Sp3以及碱性亮氨酸拉链蛋白家族,这提示了细胞和组织特异性调控的可能性。开展研究以探索hRFC在人体组织和细胞系中的表达模式。在来自76个人体组织和肿瘤细胞系的多组织mRNA芯片以及代表性组织的多组织Northern印迹上,用全长hRFC cDNA进行探针杂交,测量hRFC转录本的水平。hRFC转录本广泛表达,在胎盘中水平最高,在骨骼肌中水平最低。通过对9个组织和2个细胞系进行cDNA 5'端快速扩增分析,鉴定出包含A和B 5'非翻译区(UTR)的hRFC转录本。然而,还检测到另外5个5'UTR(命名为A1、A2、C、D和E),它们位于hRFC翻译起始位点上游超过35 kb处。这些5'UTR的特征是具有多个转录起始位点和/或可变剪接形式。至少检测到18种独特的hRFC转录本。一个新的启动子定位于一个453 bp的片段,包括外显子C上游442 bp和外显子C的11 bp。一个346 bp的阻遏物位于该启动子的3'端侧翼。我们的结果表明hRFC基因表达存在复杂的调控,涉及多个启动子和非编码外显子。此外,它们为理解hRFC在叶酸缺乏病理生理学和抗叶酸药物选择性中的作用提供了一个转录框架。